Clinical Trial Search

Primary: To Evaluate the Incidence of the Pre-proendothelin SNP at Nucleotide 5665 — 10 participants

Primary: Maximum Sildenafil Plasma Concentration — 181; 515; 545; 202 ng/mL

Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants

Primary: Pulmonary Blood Flow as Determined by MRI Velocity Encoding at 3-6 Months — 3.3; 4.4 L/min — p=0.03

Primary: Area Under the Curve for Ambrisentan Plasma Concentration — 7871.46 ng*hr/mL

Primary: Weight-for-age Z-score at 14 Months of Age — -0.62; -0.42 standard deviation — p=0.28

Primary: Proportion of Patients Who Died or Received a Heart Transplant — 100; 72 Participants — p=0.013

Primary: Number of Subjects With Left Ventricular Recovery and LVAD Explant — 8 Participants

Primary: Change From Baseline in Mean Oxygen Consumption (mL/kg/Min) at 6 Weeks — 30.5; 30.5; 31.3; 31.3 mL/kg/min — p=0.73

Primary: Impaired Post-operative Functional Capacity — 35 Participants

Primary: Peak Oxygen Uptake — 15 ml/kg/min

Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants

Primary: Number of Incidence of Treatment Related Major Adverse Cardiac Events — 1; 0; 6 Events

Primary: Time to First Post-operative Negative 24 Hour Fluid Balance — 2.7; 2.67 Days

Primary: Oxygenation Response — 4.2; 2.6 Change in Oxygenation Index

Primary: Cardiac Index — 3.39; 3.42; 3.23 L/min/m2

Primary: The Number of Graft Related Post-operative Complications That Require a Repeat Surgery or a Non Surgical Treatment Within 12-month Post Implantation. — 0 Participants

Primary: Stroke-Free Survival Probability for 2 Years Post Implant — 55.4; 59.1 Probabillity — p=0.0110

Primary: Closure of Muscular Ventricular Septal Defects — 91 participants

Primary: Freedom From Device or Procedure Related Death or Reintervention — 97.1 percentage of participants

Primary: Adverse Events (AEs) and Serious Adverse Events (SAEs) in a Passive ROM Exercise Program, Administered up to 21 Days After the Norwood Procedure, in Infants With Single…

Primary: Peak Vo2 — 33; 12.5 ml/kg/min

Primary: Mortality, Heart Failure-related Urgent Care Visits, or Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI) — 160; 191; 93; 136 participants…

Primary: Number of Participants With Acute Kidney Injury — 18; 57 Participants

Primary: The Change in Exercise Capacity Measured Via Maximum Oxygen Consumed During Exercise (VO2) — 39.4; 36.8; 41.2; 34.4 ml/min/kg

Primary: End-systolic Elastance — 0.85; 1.8 Ees in mmHg/ml/m2

Primary: Number of Participants Who Developed Infective Endocarditis — 9 participants

Primary: Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection, Serious Arrhythmia and/or Death — 303; 349 participants

Primary: Change in Flow Mediated Dilation — 5.5 Percentage of brachial artery diameter

Primary: Safety of Cell Delivery — 1; 0 adverse events